Calithera Reports the First Patient Enrollment of Sapanisertib in P-II Clinical Trial for NRF2-Mutated Squamous Non-Small Cell Lung Cancer
Shots:
- The first patient has been enrolled in the P-II trial to evaluate sapanisertib (2mg, BID or 3mg, qd) in patients with r/r NFE2L2-mutated sq. NSCLC whose disease has progressed on or after Pt-doublet CT & immune checkpoint inhibitor therapy (anti-PD-L1) with/out anti-CTLA-4. The results are expected in Q1’23
- The 1EPs of the study are investigator-assessed ORR & safety while 2EPs include DoR, PFS & OS. The trial is also intended to validate sapanisertib's selective activity for NRF2-mutated tumors over WT tumors & to optimize dosing in the biomarker-defined population
- Sapanisertib is a potent & selective mTORC 1/2 inhibitor that targets survival mechanisms in tumors harboring mutations & showed single-agent clinical activity for r/r NRF2-mutated sq.NSCLC
Ref: Bussinesswire | Image: Calithera
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
